~~<i id='A8FBFEF112'><strike id='A8FBFEF112'><tt id='A8FBFEF112'><pre id='A8FBFEF112'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-10-02 03:10:51 Page View：8377

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Senate panel passes drug pricing bills, but drops one PBM reform
Next article： Bright Health sells Medicare Advantage business to Molina

explore

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Case highlights the risks of experimental stem cell therapy

Neurons(red)andastrocytes(green)derivedfromhumanneuralstemcellsgrowinginculture.StevenPollard/Wellco